High-grade astrocytomas: Resource use, clinical outcomes, and cost of care

被引:0
|
作者
Silverstein, MD
Cascino, TL
Harmsen, WS
机构
[1] MAYO CLIN & MAYO FDN,DEPT NEUROL,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe the clinical course, survival, resource use, and direct medical costs of care for patients with high-grade astrocytomas. Material and Methods: All patients with grade 3 or 4 astrocytoma who resided in Olmsted County, Minnesota, or one of the six adjacent counties and had a tissue diagnosis first made between 1987 and 1992 were studied. Clinical characteristics, initial management, use of resources, clinical course, survival, and medical charges were analyzed. Results: Sixty-four patients, with a mean age of 62 years, were identified; 81% had glioblastoma multiforme. Approximately 60% underwent surgical resection, 80% had radiotherapy, and 50% had chemotherapy for initial management. After initial treatment (median duration, 116 days), approximately 75% of patients had a course with stable disease (median duration, 198 days), The overall median duration of survival was 323 days; lower grade and younger age were significantly associated with longer median survival-for example, 1,493 days for patients younger than 65 years with grade 3 astrocytomas and 205 days for patients 65 gears old or older with grade 4 astrocytomas. The mean total direct medical charges were $67,887. Conclusion: In most patients with high-grade astrocytomas, a substantial period elapsed before disease progressed. Although the overall median duration of survival was less than I year, younger patients, especially those with grade 3 astrocytomas, had a longer survival. The management of patients with high-grade astrocytomas uses substantial health-care resources.
引用
收藏
页码:936 / 944
页数:9
相关论文
共 50 条
  • [1] HIGH-GRADE ASTROCYTOMAS
    WEN, PY
    FINE, HA
    BLACK, PM
    SHRIEVE, DC
    ALEXANDER, E
    LOEFFLER, JS
    NEUROLOGIC CLINICS, 1995, 13 (04) : 875 - &
  • [2] THE CHEMOTHERAPY OF HIGH-GRADE ASTROCYTOMAS
    LESSER, GJ
    GROSSMAN, S
    SEMINARS IN ONCOLOGY, 1994, 21 (02) : 220 - 235
  • [3] RADIOSENSIBILITY OF HIGH-GRADE ASTROCYTOMAS
    MORNEX, F
    BERTRAND, S
    NGUYEN, MJ
    BURONFOSSE, A
    DORE, JF
    PATHOLOGIE BIOLOGIE, 1994, 42 (10): : 932 - 933
  • [4] High-grade astrocytomas in children
    Rivlin, KA
    Finlay, JL
    CRITICAL REVIEWS IN NEUROSURGERY, 1996, 6 (02) : 110 - 113
  • [5] ROLE OF SURGERY FOR HIGH-GRADE ASTROCYTOMAS
    GASPAR, LE
    SCHOLD, SC
    CAIRNCROSS, JG
    JOURNAL OF NEUROSURGERY, 1991, 74 (06) : 1027 - 1028
  • [6] Evolutionary etiology of high-grade astrocytomas
    Song, Yurong
    Zhang, Qian
    Kutlu, Burak
    Difilippantonio, Simone
    Bash, Ryan
    Gilbert, Debra
    Yin, Chaoying
    O'Sullivan, T. Norene
    Yang, Chunyu
    Kozlov, Serguei
    Bullitt, Elizabeth
    McCarthy, Ken D.
    Kafri, Tal
    Louis, David N.
    Miller, C. Ryan
    Hood, Leroy
    Van Dyke, Terry
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (44) : 17933 - 17938
  • [7] PLOIDY OF ENDOTHELIUM IN HIGH-GRADE ASTROCYTOMAS
    DAVENPORT, RD
    MCKEEVER, PE
    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 1987, 9 (01): : 25 - 29
  • [8] ROLE OF SURGERY FOR HIGH-GRADE ASTROCYTOMAS - REPLY
    NEUWELT, EA
    NAZZARO, JM
    JOURNAL OF NEUROSURGERY, 1991, 74 (06) : 1028 - 1029
  • [9] Genetic alterations in pediatric high-grade astrocytomas
    Cheng, Y
    Ng, HK
    Zhang, SF
    Ding, M
    Pang, JCS
    Zheng, J
    Poon, WS
    HUMAN PATHOLOGY, 1999, 30 (11) : 1284 - 1290
  • [10] Temozolomide -: A new option for high-grade astrocytomas
    Schwenka, J
    Ignoffo, RJ
    CANCER PRACTICE, 2000, 8 (06) : 311 - 313